Senosuppressor Program

About Atropos Therapeutics

Atropos Therapeutics is a private, preclinical-stage biotech leveraging a novel understanding of cellular senescence to develop first-in-class therapeutics. The company's core innovation is the FATES platform, a phenotypic screening technology based on the detection of ATRX foci, which aims to identify 'senosuppressors' to prevent harmful senescence in aging and 'senostimulators' to induce beneficial senescence in cancer. With a seasoned leadership team and scientific advisory board, Atropos is positioned in the rapidly growing longevity and senotherapeutics space, though it faces significant technical and competitive risks inherent to pioneering a new drug discovery approach.

Therapeutic Areas